Amplify Weight Loss Drug & Treatment ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.
Amplify Weight Loss Drug & Treatment ETF THNR
Morningstar’s Analysis THNR
Will THNR outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 61.5
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Novo Nordisk AS ADR | 10.18 | 518,276 | Healthcare |
Eli Lilly and Co | 8.88 | 451,879 | Healthcare |
Innovent Biologics Inc | 5.68 | 289,035 | Healthcare |
CSPC Pharmaceutical Group Ltd | 5.45 | 277,524 | Healthcare |
Scholar Rock Holding Corp | 5.30 | 269,967 | Healthcare |
Hims & Hers Health Inc Ordinary Shares - Class A | 5.30 | 269,742 | Healthcare |
Regeneron Pharmaceuticals Inc | 5.29 | 269,532 | Healthcare |
AbbVie Inc | 5.28 | 268,583 | Healthcare |
Viking Therapeutics Inc | 5.16 | 262,846 | Healthcare |
Amgen Inc | 4.94 | 251,641 | Healthcare |